What OptraScan does

OptraScan (legal entity OptraSCAN USA, Inc., founded 2015–2016, headquartered in San Jose, CA with an engineering and product development office in Pune, India) is a private digital pathology company that designs and manufactures whole-slide scanners and the surrounding AI-driven image management, telepathology, and disease-specific analysis software. The company's core technical asset is OS-SiA, a US-patented Simultaneous Scan-Index-Analyze technology that performs real-time AI inference during slide acquisition rather than as a post-processing step; this is paired with a separately patented composite imaging method for extended depth of field. The scanner portfolio spans the compact 6-slide OS-SiX, the 15-slide OS-Lite, the high-capacity 80–480-slide OS-Ultra, the dual-mode brightfield/fluorescence OS-FLi, and the intraoperative OS-FS frozen section system. On top of the hardware layer, IMAGEPath provides HIPAA-compliant image management and HL7/API integration to LIS, PACS, LIMS, and HIS systems, while TELEPath enables remote pathologist consultation. Disease-specific AI applications include BactoSiA (TB smear microscopy aligned with WHO grading), CytoSiA (cervical cancer Bethesda classification), HistoSiA Breast (HER2, ER, PR, Ki-67, AE1/3 with Allred/H-Score/ASCO-CAP outputs), plus algorithms for lung PD-L1 (published in Nature), prostate Gleason grading, and Virtual IHC staining.

The business model combines scanner hardware sales (with bundled first-year software licenses) and three software/AI monetization paths: annual subscriptions for IMAGEPath and TELEPath, pay-per-use AI pricing (notably HistoSiA Breast), and per-slide/per-case AI analysis fees. Go-to-market is primarily direct enterprise field sales organized regionally across USA, MEA, and India, supplemented by technology integration partnerships (Paige, Lumea, Karkinos Healthcare), NGO and public-health program channels for screening deployments, and — following Molbio Diagnostics' ~$30M majority-stake acquisition in November 2024 — Molbio's distribution network, particularly in India and global health markets. The platform is certified to ISO 13485:2016, CE-IVDR (EU 2017/746), and CDSCO (India), with HIPAA-compliant cloud and 21 CFR Part 11 software compliance. Customer base spans 46+ disclosed logos across hospital pathology labs, pharmaceutical/CRO research, national screening programs, medical education, and mobile/NGO units, including DBT-validated deployments across 9 hospitals and 10,000 patients in India.

Name

OptraScan

Legal name

OptraSCAN USA, Inc.

Website

https://optrascan.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

OptraScan (OptraSCAN USA, Inc.) builds AI-enabled whole-slide scanners and digital pathology software — IMAGEPath image management, TELEPath telepathology, and disease-specific AI for TB, cervical, breast, lung, and prostate cancer — sold to hospital pathology labs, pharma/CROs, public-health screening programs, and academic institutions globally.

Ownership category

akta.pro rank

Product category

Digital Pathology Systems

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)

Keywords

• Digital pathology
• Whole slide imaging
• Pathology imaging scanners
• Telepathology platforms
• Cancer biomarker analysis

Headquarters

HQ city

San Jose

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Whole Slide Scanner Hardware Sales: Sale of digital pathology scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi). Hardware is sold with bundled software licenses (1-year IMAGEPath license). Pricing models include purchase and leasing options. Scanners range from compact 6-slide capacity to high-throughput 480-slide systems.
2. Software Subscriptions and Licenses: Recurring revenue from IMAGEPath image management software licenses, TELEPath telepathology platform, and AI analytics modules. Software is offered as cloud-based or on-premise solutions with annual subscription billing.
3. Pay-Per-Use / On-Demand Solutions: On-Demand Digital Pathology model allowing customers to pay only for what they use. HistoSiA Breast specifically launched on pay-per-use model. Enables flexible adoption with minimum upfront investment, targeting labs of all sizes and resource-limited settings.
4. AI-Assisted Diagnostic Solutions: AI-powered analysis solutions including BactoSiA (TB), CytoSiA (cervical cancer), HistoSiA (breast cancer), and cancer biomarker analysis algorithms. Revenue from per-slide or per-case analysis fees, or bundled with scanner/software purchases.
5. Professional Services and Support: Technical support services including 24x7 global technical support, installation, training, and on-site maintenance. Professional services for implementation, integration with LIS/PACS systems, and regulatory compliance support.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

OptraScan develops and sells whole-slide imaging scanners, AI-driven pathology analytics software, and cloud-enabled image management and telepathology platforms. Its core differentiator is the patented OS-SiA technology, which simultaneously scans, indexes, and performs AI analysis on tissue slides in a single step during image acquisition, reducing diagnostic turnaround time from hours to minutes. The integrated portfolio spans hardware scanners, AI disease-specific solutions (BactoSiA for TB, CytoSiA for cervical cancer, HistoSiA Breast for breast cancer biomarkers), the IMAGEPath workflow platform, and TELEPath remote consultation tools, sold to pathology laboratories, hospitals, pharma, and public health programs worldwide.

Product overview

OptraScan offers an integrated digital pathology ecosystem combining whole slide scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi) with AI-powered software platforms and analysis solutions. The core of the portfolio is the patented OS-SiA technology, which enables simultaneous scanning, indexing, and real-time AI analysis during slide acquisition — reducing diagnostic turnaround time from hours to minutes. This technology powers specialized AI solutions including BactoSiA for tuberculosis detection, CytoSiA for cervical cancer screening, and HistoSiA Breast for breast cancer biomarker analysis. The IMAGEPath platform provides HIPAA-compliant image management and archival, while TELEPath enables telepathology consultations. The portfolio also includes standalone cancer analysis modules for breast, cervical, lung, and prostate cancer, plus Virtual IHC staining for reagent-free biomarker visualization, all supported by a cloud-based E-Learning pathology education platform.

Differentiator

Problem solved

Functional benefit

Brands

• BactoSiA: AI-assisted tuberculosis treatment monitoring solution that digitizes and standardizes sputum smear microscopy workflows using high-resolution whole-slide imaging and AI algorithms.
• CytoSiA
• HistoSiA Breast
• IMAGEPath
• TELEPath
• OptraSCAN Pathology E-Learning Platform
• OS-SiA
• OS-FS

Products and services

• OS-SiX Whole Slide Scanner Compact 6-slide brightfield whole-slide scanner with integrated AI-powered scanning, indexing, and analysis via OS-SiA technology. Scans 6 standard slides or 3 mega slides in 120 seconds at 20x and 240 seconds at 40x. Designed for low-to-mid-volume pathology labs with limited space.
• OS-Lite Whole Slide Scanner 15-slide brightfield whole-slide scanner with automated tissue detection and cloud-enabled image management. Scans a 15x15mm area in 40 seconds at 20x or 90 seconds at 40x, with patented composite imaging for extended depth of field.
• OS-Ultra Whole Slide Scanner High-capacity brightfield whole-slide scanner with 80 to 480 slide capacity and sub-minute scanning speeds. Features no-touch and continuous slide loading for high-throughput environments, with 0.25 microns per pixel resolution and embedded IMAGEPath/TELEPath software.
• OS-FLi Fluorescence and Brightfield Scanner Dual-purpose fluorescence and brightfield whole-slide scanner combining high-resolution fluorescence and brightfield imaging in a single platform. Supports multichannel fluorescence for FISH analysis, IHC quantification, high-content screening, and biomarker discovery.
• OS-FS Frozen Section Imaging Real-time frozen section imaging modality for intraoperative pathology review. Features Live View Mode for instant digital microscopy without archived whole-slide imaging, supporting 7-slide frozen or 15-slide FFPE cartridge options. Integrates with IMAGEPath and TELEPath.
• OS-SiA Patented AI Technology Platform World's first patented AI-powered digital pathology technology that scans, indexes, and analyzes tissue simultaneously during slide acquisition. Transforms scanners from passive image-capture devices into active diagnostic systems, performing on-device AI analytics and reducing diagnostic turnaround from hours to minutes.
• BactoSiA AI Tuberculosis Solution AI-assisted tuberculosis treatment monitoring solution that digitizes sputum smear microscopy and automatically detects and grades acid-fast bacilli using WHO-aligned standardized criteria (Scanty, 1+, 2+, 3+). Targets public health labs, TB labs, mobile units, and telepathology networks.
• CytoSiA Digital Cytology Platform AI-powered digital cytology platform for cervical cancer screening. Triages normal and abnormal cases, classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), and generates structured clinician-ready reports. Designed for national cervical screening programs and mid-to-high-volume cytology labs.
• HistoSiA Breast Cancer AI Suite AI-enabled breast cancer biomarker analysis suite that performs automated HER2 categorization (0, 1+, 2+, 3+) during slide scanning and supports IHC analysis for HER2, ER, PR, Ki-67, and AE1/3 biomarkers. Includes Allred, H-Score, ASCO-CAP, and TNM staging tools. Available on a pay-per-use pricing model.
• Breast Cancer Analysis Algorithm Digital pathology algorithm for identifying and quantifying breast cancer tumor characteristics including tissue area, tumor area, DCIS, and invasive carcinoma. Supports biomarker evaluation for ER, PR, HER2Neu, Ki67, and P53. Validated across 9 hospitals and 10,000 patients, certified by India's DBT.
• Cervical Cancer Analysis Algorithm AI-powered machine learning algorithm for identifying precancerous lesions and cancerous cells in cervical cytology samples. Distinguishes normal from abnormal cells and classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), generating Bethesda-format reports.
• Lung Cancer PD-L1 Analysis Algorithm Automated PD-L1 lung cancer algorithm evaluating PD-L1 expression in tumor and immune cells. Detects partial and complete membrane staining on tumor cells and membrane/cytoplasmic staining on immune cells, generating PD-L1 scores relative to total tumor cells. Validates at least 100 viable tumor cells per sample. Research published in Nature.
• Prostate Cancer Gleason Analysis Algorithm AI-driven prostate cancer biomarker analysis algorithm with deep learning-based Gleason grading on H&E-stained digital slides. Provides consistent Gleason grade classification for prognostication and treatment planning, with evaluation of key prostate cancer biomarkers.
• Virtual IHC Staining AI-driven virtual immunohistochemistry staining technology that digitally transforms H&E-stained slides into high-fidelity IHC-equivalent images without physical staining. Eliminates need for chemical reagents, enables multiplex biomarker analysis on a single section, and provides standardized reproducible results.
• IMAGEPath Image Management System Digital pathology image management and workflow software for organizing, viewing, sharing, and archiving whole-slide images. Supports HIPAA-compliant cloud and local storage up to 10TB, interactive viewing with annotation and measurement, side-by-side comparison, role-based access, audit trails, and HL7/API integration with LIS, PACS, LIMS, and HIS.
• TELEPath Telepathology Platform Telepathology software platform for real-time remote consultation and collaboration among pathologists. Facilitates remote sharing and viewing of digital slide images for consultations, second opinions, and multidisciplinary team meetings with live chat and conferencing.
• Pathology E-Learning Platform Cloud-based digital pathology education platform consolidating whole-slide images, course materials, assignments, and assessments. Supports teacher workflows (course creation, slide upload, annotation, live teleconsultation) and student workflows (WSI exploration, annotation review, assignment completion). Includes role-based access and performance tracking dashboards.

Quantifiable outcome

• Reduces diagnostic turnaround time from hours to minutes through real-time simultaneous scan-index-analyze
• +6 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature13 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Philips (IntelliSite Pathology): Philips offers IntelliSite digital pathology scanners and enterprise pathology workflow software as part of a broad hospital IT and diagnostic imaging portfolio. Directly competes with OptraScan in whole slide imaging and image management for large hospital systems.
• Leica Biosystems (Aperio, Danaher): Leica Biosystems (owned by Danaher) provides Aperio whole slide scanners and pathology workflow software with broad installed base globally. Directly competes with OptraScan's OS-Ultra and IMAGEPath offerings across clinical pathology labs.
• Roche (Ventana DP 200): Roche's Ventana slide scanning and digital pathology solutions are bundled with its dominant IHC and companion diagnostics franchise. Competes with OptraScan in integrated hardware-software-AI workflows for hospital pathology labs, especially in oncology.

Direct peers

• Hamamatsu Photonics (NanoZoomer): Hamamatsu's NanoZoomer is one of the most widely deployed whole slide scanner families globally, including fluorescence and brightfield models. Closely comparable to OptraScan's OS-SiX, OS-Lite, OS-Ultra, and OS-FLi scanner portfolio targeting clinical and research pathology labs.
• 3DHistech: 3DHistech provides PANNORAMIC whole slide scanners, digital pathology workflow software, and AI applications across clinical and research markets. Directly competes with OptraScan across scanner hardware, image management, and AI analytics for pathology.
• Sakura Finetek: Sakura Finetek provides digital pathology and histology workflow solutions including scanners and tissue processing equipment. Overlaps with OptraScan's OS scanner line and broader digital pathology workflow for clinical and research labs.
• Huron Digital Pathology: Huron offers whole slide scanners (TissueScope) and image management software targeted at clinical and research pathology. A comparable mid-market scanner + software peer to OptraScan's OS-SiX/Lite/Ultra and IMAGEPath stack.
• Motic Digital Pathology: Motic provides EasyScan and other whole slide scanners with integrated software for clinical, veterinary, and education markets. Competes with OptraScan's compact OS-SiX and OS-Lite scanners in mid-volume and education-focused pathology labs.

Emerging players

• Paige.AI: Paige develops AI-only clinical decision support for pathology, including FDA-authorized prostate and breast cancer applications. Has an explicit partnership with OptraScan, but as an AI-native player Paige could also be seen as an emerging alternative to OptraScan's own AI modules.
• Ibex Medical Analytics: Ibex develops AI-powered cancer diagnostics for pathology, including breast and prostate applications with CE marks and Galen platform. An AI-native emerging player whose modules can substitute for some of OptraScan's cancer analysis algorithms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC2SY8X6C1a6E1eWdV9C0J_A
• LinkedInlinkedin.com/company/optra-ventures-pvt-ltd
• Xx.com/optrascan

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OptraScan